RxDoctor Payments Data

Karen Carreiro

Procedural Dermatology · Fall River, MANPI 1578073128

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 289 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 28.9% of the total. Reporting peaked in 2023 at $2,073 and has fallen 86.0% since, to $291 in 2025.

$5,999in general payments, 2019–2025

Across 289 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$913
  • Novartis$744
  • UCB, Inc.$572
  • E.r. Squibb & Sons, L.L.C.$334
  • Lilly USA, LLC$263
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$5,92699%
  • Education$731%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few procedural dermatology providers in Massachusettsto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$39,542
Medicare patients
167
Services billed
818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tacrolimus33$4,354
Clobetasol Propionate65$2,170
Fluorouracil29$2,053
Ketoconazole76$1,140
Metronidazole12$718
Triamcinolone Acetonide57$645
Ammonium Lactate25$370
Terbinafine Hcl13$16

Paid to pharmacies, not to this prescriber.

Other procedural dermatology in Fall River

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →